09:09 AM EDT, 10/21/2025 (MT Newswires) -- Viking Therapeutics ( VKTX ) said Tuesday it initiated a phase 1 clinical trial, testing maintenance dosing of its obesity drug candidate VK2735 in adults with obesity.

The company said the study will enroll about 180 participants to assess monthly subcutaneous, weekly oral, and daily oral dosing regimens after an initial 19-week period of weekly subcutaneous dosing.

The trial will measure safety, tolerability, and drug exposure, with exploratory endpoints of tracking body weight change from baseline and from week 19 to week 31, the company said, adding that results are expected in 2026.

The company is also running two phase 3 trials, Vanquish-1 and Vanquish-2, evaluating weekly subcutaneous VK2735 in patients with and without type 2 diabetes.